Drugs /
ribociclib
Overview
Biomarker-Directed Therapies
Clinical Trials
Ribociclib has been investigated in 65 clinical trials, of which 53 are open and 12 are closed. Of the trials investigating ribociclib, 2 are early phase 1 (2 open), 21 are phase 1 (17 open), 9 are phase 1/phase 2 (8 open), 23 are phase 2 (19 open), and 10 are phase 3 (7 open).
ER Positive, HER2 Deficient Expression, and HER2 Negative are the most frequent biomarker inclusion criteria for ribociclib clinical trials.
Breast carcinoma, malignant solid tumor, and ovarian carcinoma are the most common diseases being investigated in ribociclib clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.